Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastim
Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastim
复制标题
对于先前单独使用非格司亭（粒细胞集落刺激因子）或化疗加非格司亭动员失败的患者，添加 ancestim（干细胞因子）后成功动员外周血干细胞
DOI：
10.1038/sj.bmt.1703860
复制
发表时间：
2003
影响因子：
4.8
通讯作者：
Brian Cohen
中科院分区：
文献类型：
--
作者：
L. B. To;John Bashford;Simon Durrant;Jamie Macmillan;A. Schwarer;H. M. Prince;J. Gibson;Ian D. Lewis;B. Swart;J. Marty;T. Rawling;L. Ashman;S. Charles;Brian Cohen
总结：本研究评估了重组人干细胞因子（rHuSCF）在44例既往非格司亭单药或化疗加非格司亭动员失败（CD 34+产量0.5-1.9 × 106/kg BW）的患者中动员干细胞的能力。使用相同的动员方案，加入rHuSCF。在非格司亭单独组（n=13）中，在非格司亭前3天开始rHuSCF 20 μg/kg，并持续非格司亭的持续时间。化疗+非格司亭组（n=31），rHuSCF 20 μg/kg/d+非格司亭5-10 μg/kg/d。白细胞单采术最多持续4次或目标值为≤ 3 × 106个CD 34+细胞/kg。在两组中，研究动员的CD 34+产量（× 106/kg BW）均高于先前动员（中位数分别为：2.42 vs 0.84 P=0.002和1.64 vs 0.99 P=<0.001）。非格司亭单药组和化疗加非格司亭组分别有54%和45%的患者达到2 × 106/kg的阈值产量。动员前CD 34+产量为0.5-0.75 × 106/kg BW的受试者成功动员的概率与CD 34+产量为0.76-1.99 × 106/kg BW的受试者相同。成功动员者的c-kit表达下调，动员后的CD 34+细胞Thy-1阳性率较低。这项研究表明，rhuSCF对大约一半先前动员失败的患者有效，并允许他们进行移植。它还指出SCF/c-kit配体对在动员中的可能作用。
Summary:This study assessed the ability of recombinant human stem cell factor (rHuSCF) to mobilize stem cells in 44 patients who had failed a prior mobilization (CD34+ yield 0.5–1.9 × 106/kg BW) with filgrastim-alone or chemotherapy-plus-filgrastim. The same mobilization regimen was used with the addition of rHuSCF. In the filgrastim-alone group (n=13), rHuSCF 20 μg/kg was started 3 days before filgrastim and continued for the duration of filgrastim. In the chemotherapy-plus-filgrastim group (n=31), rHuSCF 20 μg/kg/day plus filgrastim 5–10 μg/kg/day were administered concurrently. Leukaphereses were continued to a maximum of four procedures or a target of ⩾3 × 106 CD34+ cells/kg. In both groups, CD34+ yield (× 106/kg BW) of the study mobilization was higher than that of the prior mobilization (median: 2.42 vs 0.84 P=0.002 and 1.64 vs 0.99 P=<0.001, respectively). In all 54 and 45% of patients in the filgrastim-alone group and chemotherapy-plus-filgrastim group, respectively, reached the threshold yield of 2 × 106/kg. The probability of a successful mobilization was the same in those with a CD34+ yield of 0.5–0.75 × 106/kg BW in the prior mobilization as in those with 0.76–1.99 × 106/kg BW. Downmodulation of c-kit expression and a lower percentage of Thy-1 positivity in the mobilized CD34+ cells were noted in the successful mobilizers compared with those in the poor mobilizers. This study shows that rhuSCF is effective in approximately half the patients who had failed a prior mobilization and allows them to proceed to transplant. It also points to the likely role of the SCF/c-kit ligand pair in mobilization.
一项在高危乳腺癌患者中使用干细胞因子和非格司亭动员外周血祖细胞的随机 3 期研究。
影响因子：
20.3
作者：
Shpall,EJ;Wheeler,CA;Turner,SA;Yanovich,S;Brown,RA;Pecora,AL;Shea,TC;Mangan,KF;Williams,SF;LeMaistre,CF;Long,GD;Jones,R;Davis,MW;Murphy-Filkins,R;Parker,WR;Glaspy,JA
通讯作者：
Glaspy,JA
影响因子：
20.3
作者：
C. Dubois;F. Ruscetti;J. Stankova;J. Keller
通讯作者：
C. Dubois;F. Ruscetti;J. Stankova;J. Keller